Teligent announced that the Food and Drug Administration (FDA) has approved Triamcinolone Acetonide Ointment, 0.1%.
Triamcinolone Acetonide Ointment is a topical steroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical corticosteroids share anti-inflammatory antipruritic and vasoconstrictive properties. The exact mechanism of anti-inflammatory activity is unclear but some evidence suggests that a correlation exists between vasoconstrictor potency and therapeutic efficacy.
Teligent’s Triamcinolone Acetonide Ointment 1% will be available as 15g and 80g tubes and a 1lb jar. It is expected to launch in the second quarter of 2016.
For more information call (856) 697-1441 or visit Teligent.com.